Hypertension. 2004;43:963-969
Published online before print March 22, 2004, doi: 10.1161/01.HYP.0000125726.92964.ab
Published online before print March 22, 2004, doi: 10.1161/01.HYP.0000125726.92964.ab
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:963.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
From Dipartimento Malattie Cardiovascolari, Università di Perugia–Ospedale Silvestrini (P.V., F.A., C.B., L.F., S.N., C.B.C.P.), Italy; Dipartimento di Medicina Interna (G.R.), Università di Perugia, Italy; and Ospedale Beato, G. Villa, Città della Pieve (R.G.).
Correspondence to Dr Paolo Verdecchia, Dipartimento Malattie Cardiovascolari, Università di Perugia, Ospedale R. Silvestrini S. Andrea delle Fratte 06122 Perugia, Italy. E-mail verdec{at}tin.it
Diabetes may develop in nondiabetic hypertensive subjects during treatment, but the long-term cardiovascular implications of this phenomenon are not clear. We determined the prognostic value of new diabetes in hypertensive subjects. In a long-term cohort study, 795 initially untreated hypertensive subjects, 6.5% of whom with type 2 diabetes, underwent diagnostic procedures including 24-hour ambulatory blood pressure (BP) monitoring and electrocardiography (ECG). Procedures were repeated after a median of 3.1 years in the absence of cardiovascular events. Follow-up duration was 1 to 16 years (median 6.0). New diabetes occurred in 5.8% of subjects initially without diabetes. Antihypertensive treatment included a diuretic in 53.5% of these subjects, versus 30.4% of those in whom diabetes did not develop (P=0.002). Plasma glucose at entry (P=0.0001) and diuretic treatment on follow-up (P=0.004) were independent predictors of new diabetes. Subsequent to the follow-up visit, a first cardiovascular event occurred in 63 subjects. Event rate in nondiabetic subjects at both visits, new diabetes, and diabetes at entry were 0.97, 3.90, and 4.70x100 person-years, respectively (P=0.0001). After adjustment for several confounders, including 24-hour ambulatory BP, the relative risk of events was 2.92 (95% CI: 1.33 to 6.41; P=0.007) in the group with new diabetes and 3.57 (95% CI: 1.65 to 7.73; P=0.001) in the group with previous diabetes, when compared with the group persistently free of diabetes. In treated hypertensive subjects, occurrence of new diabetes portends a risk for subsequent cardiovascular disease that is not dissimilar from that of previously known diabetes.
Key Words: hypertension • echocardiography • hypertrophy • blood pressure • epidemiology • diuretics
This article has been cited by other articles:
 |
|
 |
|
  B. L. Carter, P. T. Einhorn, M. Brands, J. He, J. A. Cutler, P. K. Whelton, G. L. Bakris, F. L. Brancati, W. C. Cushman, S. Oparil, et al. Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute Hypertension, July 1, 2008; 52(1): 30 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Messerli, S. Bangalore, and S. Julius Risk/Benefit Assessment of {beta}-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension Circulation, May 20, 2008; 117(20): 2706 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Gupta, B. Dahlof, J. Dobson, P. S. Sever, H. Wedel, N.R. Poulter, and on behalf of the Anglo-Scandinavian Cardiac Outcom Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication Diabetes Care, May 1, 2008; 31(5): 982 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Wright Jr, S. Harris-Haywood, S. Pressel, J. Barzilay, C. Baimbridge, C. J. Bareis, J. N. Basile, H. R. Black, R. Dart, A. K. Gupta, et al. Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, January 28, 2008; 168(2): 207 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, K. E. Harris, S. Jern, S. E. Kjeldsen, L. H. Lindholm, B. Dahlof, and for the LIFE Study Investigators In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study Hypertension, November 1, 2007; 50(5): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Reungjui, C. A. Roncal, W. Mu, T. R. Srinivas, D. Sirivongs, R. J. Johnson, and T. Nakagawa Thiazide Diuretics Exacerbate Fructose-Induced Metabolic Syndrome J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Aksnes, S. E. Kjeldsen, M. Rostrup, P. Omvik, T. A. Hua, and S. Julius Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population Hypertension, September 1, 2007; 50(3): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, F. Angeli, and G. Reboldi New-Onset Diabetes, Antihypertensive Treatment, and Outcome Hypertension, September 1, 2007; 50(3): 459 - 460. [Full Text] [PDF]
|
|
|
|
|
|
C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rosenthal, E. Rosenmann, D. Tomassoni, and F. Amenta Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 145 - 152. [Abstract] [PDF]
|
|
|
|
|
|
C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
|
|
G. Bakris, M. Molitch, A. Hewkin, M. Kipnes, P. Sarafidis, K. Fakouhi, P. Bacher, J. Sowers, and on behalf of the STAR Investigators Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome Diabetes Care, December 1, 2006; 29(12): 2592 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Phillips New-onset diabetes mellitus less deadly than elevated blood pressure?: following the evidence in the administration of thiazide diuretics. Arch Intern Med, November 13, 2006; 166(20): 2174 - 2176. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Barzilay, B. R. Davis, J. A. Cutler, S. L. Pressel, P. K. Whelton, J. Basile, K. L. Margolis, S. T. Ong, L. S. Sadler, J. Summerson, et al. Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, November 13, 2006; 166(20): 2191 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cutler Thiazide-Associated Glucose Abnormalities: Prognosis, Etiology, and Prevention: Is Potassium Balance the Key? Hypertension, August 1, 2006; 48(2): 198 - 200. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Zillich, J. Garg, S. Basu, G. L. Bakris, and B. L. Carter Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review Hypertension, August 1, 2006; 48(2): 219 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sarafidis and G. L. Bakris Antihypertensive Therapy and the Risk of New-Onset Diabetes Diabetes Care, May 1, 2006; 29(5): 1167 - 1169. [Full Text] [PDF]
|
|
|
|
|
|
D. Thornley-Brown, X. Wang, J. T. Wright Jr, O. S. Randall, E. R. Miller, J. P. Lash, J. Gassman, G. Contreras, L. J. Appel, L. Y. Agodoa, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med, April 10, 2006; 166(7): 797 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Salvetti and L. Ghiadoni Thiazide Diuretics in the Treatment of Hypertension: An Update J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S25 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Volpe, G. Tocci, and E. Pagannone Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S36 - S43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Morganti Randomized Clinical Trials on Surrogate End Points: Are They Useful for Evaluating Cardiovascular and Renal Disease Protection in Hypertension? The Case for Yes J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S141 - S144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, R. B. Devereux, E. Gerdts, S. M. Snapinn, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, L. H. Lindholm, et al. Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Circulation, March 28, 2006; 113(12): 1588 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Pepine, P. R. Kowey, S. Kupfer, R. E. Kolloch, A. Benetos, G. Mancia, A. Coca, R. M. Cooper-DeHoff, E. Handberg, E. Gaxiola, et al. Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 547 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Narkiewicz Obesity and hypertension--the issue is more complex than we thought Nephrol. Dial. Transplant., February 1, 2006; 21(2): 264 - 267. [Full Text] [PDF]
|
|
|
|
|
|
R. Cooper-DeHoff and C. J. Pepine Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes Eur. Heart J., January 1, 2006; 27(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kaplan Treatment of Hypertension: Remaining Issues After the Anglo-Scandinavian Cardiac Outcomes Trial Hypertension, January 1, 2006; 47(1): 10 - 13. [Full Text] [PDF]
|
|
|
|
|
|
S. Nathan, C. J. Pepine, and G. L. Bakris Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients Hypertension, October 1, 2005; 46(4): 637 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kario, J. Ishikawa, S. Hoshide, Y. Matsui, M. Morinari, K. Eguchi, S. Ishikawa, and K. Shimada Diabetic Brain Damage in Hypertension: Role of Renin-Angiotensin System Hypertension, May 1, 2005; 45(5): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Williams Recent hypertension trials: Implications and controversies J. Am. Coll. Cardiol., March 15, 2005; 45(6): 813 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Morganti Should a Diuretic Always Be the First Choice in Patients with Essential Hypertension? The Case for No J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S70 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Pepine and R. M. Cooper-DeHoff Cardiovascular therapies and risk for development of diabetes J. Am. Coll. Cardiol., August 4, 2004; 44(3): 509 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Hypertensive Drug Treatment, New-Onset Diabetes, and CV Risk Journal Watch Cardiology, July 9, 2004; 2004(709): 4 - 4. [Full Text]
|
|
|
|
|
|
G. L. Bakris and J. R. Sowers When Does New Onset Diabetes Resulting From Antihypertensive Therapy Increase Cardiovascular Risk Hypertension, May 1, 2004; 43(5): 941 - 942. [Full Text] [PDF]
|
|